Short-lived immunotherapy in early Alzheimer’s: a concise report previewing trial design, safety signals and biomarker-focused results readers will explore.
Key Takeaways
- Short-lived anti-PD-L1 antibody was safe and well tolerated in early Alzheimer’s patients
- Highest-dose recipients showed cerebrospinal fluid reductions in neurogranin, total Tau, and pTau181
- Trial achieved target engagement and supports designing a next-stage clinical protocol